New Lumigan Eye Drop Formulation for Glaucoma From Allergan Approved by FDA
September 1, 2010
Allergan has announced that the FDA has approved has approved LUMIGAN(R) (bimatoprost ophthalmic solution) 0.01% as a first-line therapy for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN(R) 0.01% is an optimized reformulation of LUMIGAN(R) (bimatoprost ophthalmic solution) 0.03%.
The approval followed a study showing that in patients with open-angle glaucoma or ocular hypertension with an average baseline of 23.5 mm Hg, LUMIGAN(R) 0.01% lowered IOP up to 7 mm Hg from baseline, with only one-third the drug exposure of LUMIGAN(R) 0.03%.
Read the full release issued by Allergan.
You might also enjoy...
- Aton Pharma Acquires Marketing Rights to Preservative-Free Timolol Product Line from Merck
- QLT Shows Positive 4 Week Efficacy in Phase II Study for Glaucoma Using Latanoprost Punctal Plug Delivery System
- Does Delaying Drug Treatment of Patients With Ocular Hypertension Increase the Risk of Glaucoma?
- Is Non-Preserved Latanoprost Superior to Xalatan for Treatment of Glaucoma?
- FDA Approves Generic Version of Xalatan® Eye Drops for Glaucoma
Jump down to form below to submit your own comments